KIMBERLY LOVETT: Open Payments
NPI 1720006125 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,793 in 155 payments from 12 companies in 2025. Trend: 2023 $241 · 2024 $1,714 · 2025 $2,793
Food & beverage: $2,650Education: $143
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $491 |
| E.R. Squibb & Sons, L.L.C. | 11 | $366 |
| ABBVIE INC. | 24 | $343 |
| Otsuka America Pharmaceutical, Inc. | 17 | $334 |
| Vanda Pharmaceuticals Inc. | 21 | $302 |
| Teva Pharmaceuticals USA, Inc. | 11 | $264 |
| Neurocrine BioSciences, Inc. | 32 | $212 |
| Lundbeck LLC | 5 | $138 |
| Alkermes, Inc. | 5 | $124 |
| Supernus Pharmaceuticals, Inc. | 6 | $123 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, FANAPT, INGREZZA, AUSTEDO XR, Qelbree.
Industry payments across MA — which companies pay providers there.
